No black box warning on record for Pristiq Extended-Release

As of the latest FDA labeling reviewed, Pristiq Extended-Release (DESVENLAFAXINE SUCCINATE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Pristiq Extended-Release medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. If it occurs, discontinue PRISTIQ and serotonergic agents and initiate supportive treatment ( 5.2 ). • Elevated Blood Pressure: Control hypertension before initiating treatment. Monitor blood pressure regularly during treatment ( 5.3 ). • Increased Risk of

No black box warning on record for Pristiq Extended-Release

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. If it occurs, discontinue PRISTIQ and serotonergic agents and initiate supportive treatment ( 5.2 ). • Elevated Blood Pressure: Control hypertension before initiating treatment. Monitor blood pressure regularly during treatment ( 5.3 ). • Increased Risk of

Pristiq Extended-Release Black Box Warning

No black box warning on record for Pristiq Extended-Release

Other warnings & precautions

Pristiq Extended-Release Black Box Warning

No black box warning on record for Pristiq Extended-Release

Other warnings & precautions